202 410

Cited 0 times in

Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective

DC FieldValueLanguage
dc.contributor.author김대준-
dc.contributor.author이익재-
dc.contributor.author이창걸-
dc.contributor.author장지석-
dc.contributor.author조병철-
dc.contributor.author차지혜-
dc.date.accessioned2017-11-01T08:33:01Z-
dc.date.available2017-11-01T08:33:01Z-
dc.date.issued2017-
dc.identifier.issn1598-2998-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/153364-
dc.description.abstractPURPOSE: The purpose of this study was to evaluate the benefits of adjuvant treatment for curatively resected thoracic esophageal squamous cell carcinoma (ESCC) and determine the optimal adjuvant treatments. MATERIALS AND METHODS: One hundred ninety-five patients who underwent a curative resection for thoracic ESCC between 1994 and 2014 were reviewed retrospectively. Postoperatively, the patients received no adjuvant treatment (no-adjuvant group, n=68), adjuvant chemotherapy (AC group, n=62), radiotherapy (RT group, n=41), or chemoradiotherapy (CRT group, n=24). Chemotherapy comprised cisplatin and 5-fluorouracil administration every 3 weeks. The median RT dose was 45.0 Gy (range, 34.8 to 59.4 Gy). The overall survival (OS), disease-free survival (DFS), locoregional recurrence (LRR), and distant metastasis (DM) rates were estimated. RESULTS: At a median follow-up duration of 42.2 months (range, 6.3 to 215.2 months), the 5-year OS and DFS were 37.6% and 31.4%, respectively. After adjusting for other clinicopathologic variables, the AC and CRT groups had a significantly better OS and DFS compared to the no-adjuvant group (p < 0.05). The LRR rate was significantly lower in the RT and CRT groups than in the no-adjuvant group (p < 0.05), whereas no significant difference was observed in the AC group. In the no-adjuvant and AC groups, 25% of patients received high-dose salvage RT due to LRR. The DM rates were similar. The anastomotic stenosis and leakage were similar in the treatment groups. CONCLUSION: Adjuvant treatment might prolong survival after an ESCC resection, and RT contributes to a reduction of the LRR. Overall, the risks and benefits should be weighed properly when selecting the optimal adjuvant treatment.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish, Korean-
dc.publisherOfficial journal of Korean Cancer Association-
dc.relation.isPartOfCANCER RESEARCH AND TREATMENT-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHBiopsy-
dc.subject.MESHCarcinoma, Squamous Cell/diagnosis-
dc.subject.MESHCarcinoma, Squamous Cell/mortality-
dc.subject.MESHCarcinoma, Squamous Cell/therapy*-
dc.subject.MESHChemoradiotherapy-
dc.subject.MESHChemotherapy, Adjuvant-
dc.subject.MESHCombined Modality Therapy-
dc.subject.MESHEsophageal Neoplasms/diagnosis-
dc.subject.MESHEsophageal Neoplasms/mortality-
dc.subject.MESHEsophageal Neoplasms/therapy*-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMultimodal Imaging/methods-
dc.subject.MESHNeoplasm Grading-
dc.subject.MESHNeoplasm Metastasis-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHRadiotherapy, Adjuvant/methods-
dc.subject.MESHRecurrence-
dc.subject.MESHRetreatment-
dc.subject.MESHSurvival Analysis-
dc.subject.MESHTreatment Outcome-
dc.titleOptimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective-
dc.typeArticle-
dc.publisher.locationKorea-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Thoracic & Cardiovascular Surgery-
dc.contributor.googleauthorKyung Hwan Kim-
dc.contributor.googleauthorJee Suk Chang-
dc.contributor.googleauthorJi Hye Cha-
dc.contributor.googleauthorIk Jae Lee-
dc.contributor.googleauthorDae Joon Kim-
dc.contributor.googleauthorByoung Chul Cho-
dc.contributor.googleauthorKyung Ran Park-
dc.contributor.googleauthorChang Geol Lee-
dc.identifier.doi10.4143/crt.2016.142-
dc.contributor.localIdA03055-
dc.contributor.localIdA03240-
dc.contributor.localIdA04658-
dc.contributor.localIdA03822-
dc.contributor.localIdA05047-
dc.contributor.localIdA00368-
dc.relation.journalcodeJ00453-
dc.identifier.eissn2005-9256-
dc.relation.journalsince2001~-
dc.identifier.pmid27338033-
dc.relation.journalbefore~2001 Journal of the Korean Cancer Research Association (대한암학회지)-
dc.subject.keywordDrug therapy-
dc.subject.keywordEsophageal neoplasms-
dc.subject.keywordRadiotherapy-
dc.subject.keywordSquamous cell carcinoma-
dc.contributor.alternativeNameKim, Dae Joon-
dc.contributor.alternativeNameLee, Ik Jae-
dc.contributor.alternativeNameLee, Chang Geol-
dc.contributor.alternativeNameChang, Jee Suk Paul-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.alternativeNameCha, Ji Hye-
dc.contributor.affiliatedAuthorLee, Ik Jae-
dc.contributor.affiliatedAuthorLee, Chang Geol-
dc.contributor.affiliatedAuthorChang, Jee Suk Paul-
dc.contributor.affiliatedAuthorCho, Byoung Chul-
dc.contributor.affiliatedAuthorCha, Ji Hye-
dc.contributor.affiliatedAuthorKim, Dae Joon-
dc.citation.titleCancer Research and Treatment-
dc.citation.volume49-
dc.citation.number1-
dc.citation.startPage168-
dc.citation.endPage177-
dc.identifier.bibliographicCitationCANCER RESEARCH AND TREATMENT, Vol.49(1) : 168-177, 2017-
dc.date.modified2017-11-01-
dc.identifier.rimsid41609-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.